Format

Send to

Choose Destination
Ann Pharmacother. 2005 Mar;39(3):502-7. Epub 2005 Jan 18.

Insulin detemir--a new basal insulin analog.

Author information

1
Department of Pharmacy Practice, School of Pharmacy-Boston, Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Avenue, Boston, MA 02115-5804, USA. jgoldman-levine@bos.mcphs.edu

Abstract

OBJECTIVE:

To review the pharmacology, pharmacokinetics, clinical trial data, adverse effects, and role in therapy of insulin detemir.

DATA SOURCES:

Articles and meeting abstracts were identified through searches of MEDLINE (1996-June 2004), EMBASE (1980-June 2004), and International Pharmaceutical Abstracts (1970-June 2004) databases, and unpublished information was provided by the manufacturer.

STUDY SELECTION AND DATA EXTRACTION:

All available studies relating to insulin detemir's pharmacology were selected. Only human studies were used for pharmacokinetic, drug interaction, efficacy, and safety data.

DATA SYNTHESIS:

Insulin detemir is a basal insulin analog that has been shown to improve glycemic control in patients with type 1 and type 2 diabetes.

CONCLUSIONS:

Insulin detemir offers some benefits over NPH for use as basal insulin in patients with type 1 and type 2 diabetes.

PMID:
15657117
DOI:
10.1345/aph.1E334
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center